Protego以1.3亿美元推进新型淀粉样变性药物研发
With $130M, Protego pushes forward a new type of amyloidosis drug
生物技术与制药领域的最新动态
With $130M, Protego pushes forward a new type of amyloidosis drug
Quadrant Capital Group LLC Purchases 3,395 Shares of Agilent Technologies, Inc. $A - MarketBeat
HSBC Upgrades Thermo Fisher Scientific to Buy From Hold, Adjusts Price Target to $670 From $550 - MarketScreener
Redefining CAR-T speed and strength with DAR-T™: A conversation with Nicholas Kirian
Expanding access in oncology trials: The case for a paired tissue-plasma approach
Specialty pharmacy’s secret weapon: The unsung power of the enrollment form
From feedstocks to infrastructure, Indiana’s bioeconomy is on the move
Meeting patients where they are: tailored support to drive recruitment and retention
Cytiva, Veeda Lifesciences drive biopharma innovation with new host cell protein services centre - IndiaMedToday
We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt - simplywall.st
Roche: Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence (RHHBY) - Seeking Alpha
Acidocalcisome-like vacuoles constitute a feedback-controlled phosphate buffering system for the cytosol
Nanophysiology approach reveals diversity in calcium microdomains across
Individual differences in tail risk sensitive exploration using Bayes-adaptive Markov decision processes
Using step selection functions to analyse human mobility using telemetry data in infectious disease epidemiology: a case study of leptospirosis
Joint profiling of cell morphology and gene expression during in vitro neurodevelopment
Cerebellar Purkinje cell stripe patterns reveal a differential vulnerability and resistance to cell loss during normal aging in mice
Cross-species standardised cortico-subcortical tractography
Complex opioid-driven modulation of glutamatergic and cholinergic neurotransmission in a GABAergic brain nucleus associated with emotion, reward, and addiction
C. elegans food choice exhibits effort discounting-like behavior